# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...
VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dependent exp...
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $...
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...